Early Onset of Alzheimer's Disease it's Variant and its Herbal Managerial Tools

Early-onset Alzheimer’s disease (EOAD), defined by symptom onset before the age of 65, represents a rare but clinically significant subset of Alzheimer’s disease (AD). EOAD is marked by greater genetic influence, rapid progression, and frequent atypical variants including posterior cortical atrophy, logopenic primary progressive aphasia, frontal variant, and corticobasal presentations. These forms often present with non-amnestic symptoms such as visuospatial, language, or executive dysfunction, complicating diagnosis and management. Standard pharmacological treatments, including cholinesterase inhibitors and memantine, provide only symptomatic relief without altering disease course. In recent years, herbal and nutraceutical interventions have gained attention as adjunctive strategies due to their neuroprotective, antioxidant, anti-amyloid, and anti-inflammatory properties. Prominent candidates include Ginkgo biloba, curcumin, Bacopa monnieri, Withania somnifera (ashwagandha), and huperzine A, each with mechanistic plausibility and varying levels of preclinical and clinical evidence. While some clinical studies suggest modest cognitive benefits, trial heterogeneity, small sample sizes, and issues of standardization limit strong conclusions. This review outlines the epidemiology, clinical heterogeneity, and pathophysiology of EOAD, highlighting its atypical variants, and critically evaluates the current evidence for herbal managerial tools. Despite encouraging findings, rigorous clinical trials are urgently required to validate efficacy, establish safety, and define the role of herbal medicines as adjuncts in the comprehensive management of EOAD.